�
Colon cancer	Our MIDGE-related dSLIM immuno modulator is used in this clinical study phase II/III conducted in cooperation with Aventis Pharma. dSLIM works as an immuno adjuvance. The study is in phase II/III.
��
Lymphoma	dSLIM is used in establishing a therapy of multiple myeloma, a form of non-Hodgkin's lymphoma. Multiple myeloma is a malignancy of plasma cells occuring usually in the bone marrow. The study is carried out in cooperation with the Hospital of the University of Cologne. The study is in phase II/III.
�
Kidney cancer	In cooperation with the Charite Hospital, the University Hospital Benjamin Franklin, and the Center for Somatic Gene Therapy (all in Berlin, Germany), a DNA-based cancer vaccine relying on the MIDGE-technology is developed.
FIV vaccine	Feline Immunodeficiency Virus (FIV) is a retrovirus in the same family of viruses as the human immunodeficiency virus (HIV). ). It attacks the immune system, and as a result, the cat is unable to fight off various infections and cancers.
FeLV	Feline leukemia (FeLV) is a highly contagious and commonly fatal disease of cats, it is among the most prevalent diseases in cats. The FIV and the FeLV DNA-vaccines are developed in cooperation with the veterinary hospital of Zurich.
Selected Projects in preclinical phases
Viral infections	In cooperation with an industrial partner and an US University we are developing a new therapy for viral infections. In this project we are using the MIDGE technology to shuttle an intracellular RNA anti-viral agent into target cells of the patient.
�
Chronical, Peripheral Pain	Together with the University Hospital Benjamin Franklin the MIDGE-technology is applied for a therapy of severe pain.
�
Rejection of transplants	If a patent requires a transplant the immune system may become a problem because it may identify the cells of the donated organ as antigens and attack. In collaboration the University Hospital Benjamin Franklin, we are investigating the use of MIDGE for the use in cornea transplantations and are preparing a clinical study phase I.